Lilly’s Taltz (ixekizumab) Receives Health Canada Approval for Non-Radiographic Axial Spondyloarthritis

 Lilly’s Taltz (ixekizumab) Receives Health Canada Approval for Non-Radiographic Axial Spondyloarthritis

Lilly’s Taltz (ixekizumab) Receives Health Canada Approval for Non-Radiographic Axial Spondyloarthritis

Shots:

  • The approval is based on P-lll COAST-X study assessing Taltz (80mg, q4w) vs PBO for the treatment of adult patients with nr-axSpA with objective signs of inflammation for 52wks.
  • Result: 1EPs of ASAS40 @16wks. (35% vs 19%); ASAS40 response @52wks. (30% vs 13%), met its 2EPs, showing efficacy in reducing disease activity and sacroiliac joint inflammation, improving patient function & QoL, the safety profile is consistent with the previous study
  • Taltz is a mAb that selectively binds with IL-17A cytokine and inhibits its interaction with the IL-17 receptor

Click here ­to­ read full press release/ article | Ref: Newswire Canada | Image: Everyday Health

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post